The SLowDOWN phase III RCT finds sitagliptin preserves hip bone density in women with type 2 diabetes. PICO summary and expert commentary for clinicians.
Browsing: Type 2 Diabetes
Landmark trials and recent evidence on type 2 diabetes management, glucose-lowering therapy, and outcomes.
A small RCT finds flaxseed oil reduces platelet aggregability but not other risk markers in type 2 diabetes, with no ApoE genotype effect. PICO summary and expert commentary.
A crossover RCT finds a specific probiotic strain modestly improves fasting glycaemia and beta-cell indices in metformin-treated type 2 diabetes. PICO summary and expert commentary.
A pilot RCT finds a culturally tailored WeChat-delivered programme improves self-efficacy and reduces diabetes distress in Chinese Americans with type 2 diabetes. PICO summary and commentary.
The Look AHEAD trial demonstrated that intensive lifestyle intervention targeting weight loss in overweight or obese adults with type 2 diabetes did not reduce cardiovascular events over 9.6 years despite clear differences in weight, fitness, and glycaemic control, establishing a critical negative result that informed the rationale for pharmacological obesity treatment with greater weight loss efficacy.
The REWIND trial demonstrated that dulaglutide reduces 3-point MACE in a broad type 2 diabetes population of which 69% had no established cardiovascular disease, with a significant 24% reduction in nonfatal stroke and consistent renal benefit, extending GLP-1 receptor agonist cardiovascular protection into a primary prevention context.
The SUSTAIN-6 trial demonstrated that once-weekly semaglutide reduced 3-point MACE by 26% in high-cardiovascular-risk type 2 diabetes, driven primarily by a significant 39% reduction in nonfatal stroke, while identifying a retinopathy complication signal attributable to rapid glucose lowering in patients with pre-existing retinopathy.
The LEADER trial demonstrated that liraglutide significantly reduced 3-point MACE and cardiovascular mortality in patients with type 2 diabetes and high cardiovascular risk, becoming the first GLP-1 receptor agonist CVOT to demonstrate superiority and characterising an atherosclerotic rather than heart failure protection profile distinct from SGLT2 inhibitors.
An RCT finds the AntiAGE-Biom probiotic does not lower HbA1c but shows a subgroup body-composition signal in type 2 diabetes. PICO summary and expert commentary.
An RCT finds Chester Step Test-guided post-dinner exercise lowers postprandial glucose and variability in type 2 diabetes on exercise days. PICO summary and expert commentary.